Neomycin is an aminoglycoside antibiotic agent used orally and topically to treat a wide variety of infections in the body. Neomycin is a broad-spectrum aminoglycoside antibiotic drug that is derived from the metabolic products of Streptomyces fradiae.
- Mechanism
- Curator reviewed · 3 references
Like other aminoglycoside antibiotic drugs, neomycin inhibits bacterial ribosomes by binding to the 30S ribosomal subunit of susceptible bacteria and disrupting the translational machinery of bacterial protein synthesis. Bacterial translation is normally initiated by the mRNA binding to the 30S ribosomal subunit and subsequent binding with 50S subunit for elongation.
- Primary indication
- Oral neomycin sulfate is indicated as an adjunctive therapy in hepatic coma (portal-system encephalopathy) by reducing ammonia-forming bacteria in the intestinal tract.Curator reviewed · 74 structured indications
- First approval
- Canada, 1998 · United States, 1955
- Also known as
- Fradiomycin · Kaomycine · Vonamycin
- Code names
- Caswell No. 595 · USAF CB-19
- Brand names
Resolves to
What you can answer from here — as of July 17, 2026
Which drugs share a target with Neomycin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account